Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration.

[1]  B. Brannetti,et al.  A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab , 2023, Science Translational Medicine.

[2]  Oliver C. Turner,et al.  Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events , 2023, Science Translational Medicine.

[3]  F. Igwe,et al.  Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab , 2022, Ophthalmology and Therapy.

[4]  P. Kertes,et al.  RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS , 2022, Retina.

[5]  S. Sadda,et al.  The Importance of Imaging to Identify Early Signs of Intraocular Inflammation Expert Opinion for Brolucizumab , 2022, Ophthalmologica.

[6]  C. Baumal,et al.  Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies , 2022, Acta ophthalmologica.

[7]  S. Sadda,et al.  A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2022, Retina.

[8]  I. Pearce,et al.  The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice , 2022, Eye.

[9]  D. Kilmartin.  Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy , 2022, Irish Journal of Medical Science (1971 -).

[10]  P. Kaiser,et al.  Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration , 2021, JAMA ophthalmology.

[11]  P. Kaiser,et al.  Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. , 2021, Ophthalmology. Retina.

[12]  Ivana K. Kim,et al.  Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER. , 2020, Ophthalmology.

[13]  J. Pearlman,et al.  Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab , 2020, Journal of vitreoretinal diseases.

[14]  Rishi P. Singh,et al.  HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. , 2020, Ophthalmology.

[15]  Matucci Andrea,et al.  Immunogenicity - unwanted immune responses to biological drugs - can we predict them? , 2020, Expert review of clinical pharmacology.

[16]  Atul K. Jain,et al.  Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations , 2020, American journal of ophthalmology case reports.

[17]  D. Do,et al.  Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration , 2020, American journal of ophthalmology case reports.

[18]  P. Mitchell,et al.  Age-related macular degeneration , 2018, The Lancet.

[19]  G. Jaffe,et al.  Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. , 2017, Ophthalmology.

[20]  U. Schmidt-Erfurth,et al.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology.

[21]  F. Holz,et al.  Recent developments in the treatment of age-related macular degeneration. , 2014, The Journal of clinical investigation.